NCT07819656 Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma
| NCT ID | NCT07819656 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanfang Hospital, Southern Medical University |
| Condition | Nasopharyngeal Carcinoma (NPC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,782 participants |
| Start Date | 2026-08-26 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,782 participants in total. It began in 2026-08-26 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This multicenter, prospective, observational cohort study aims to evaluate a previously developed dynamic risk prediction model for severe treatment-related myelosuppression in patients with nasopharyngeal carcinoma receiving systemic therapy. The model is designed to estimate the risk of grade 3 or higher anemia, thrombocytopenia, and leukopenia or neutropenia during treatment. Eligible adult patients with histologically confirmed nasopharyngeal carcinoma will be consecutively enrolled at participating centers. Before each cycle of systemic therapy, routinely available clinical and laboratory data will be collected and used to generate updated risk predictions. Patients will be followed throughout systemic therapy and for 28 days after the last treatment. This is an observational study. Treatment and supportive care will be determined by treating physicians according to routine clinical practice. Model predictions will be used only for research evaluation and will not be used to guide or modify patient treatment. The study will evaluate the predictive performance and clinical applicability of the model across multiple centers.
Eligibility Criteria
Inclusion Criteria: * Voluntary provision of written informed consent. * Age ≥18 years. * Histologically confirmed nasopharyngeal carcinoma. * Patients who, in the judgment of the treating physician, require systemic anticancer treatment. Exclusion Criteria: * Presence of other uncontrolled serious diseases, including unstable cardiac disease requiring treatment, poorly controlled diabetes mellitus (fasting blood glucose \>1.5 times the upper limit of normal), psychiatric disorders, or a history of severe allergy. * Considered unsuitable for participation in the study by the investigator.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07819656 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Nasopharyngeal Carcinoma (NPC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07819656 currently recruiting?
Yes, NCT07819656 is actively recruiting participants. Contact the research team at 51643930@qq.com for enrollment information.
Where is the NCT07819656 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT07819656 clinical trial?
NCT07819656 is sponsored by Nanfang Hospital, Southern Medical University. The trial plans to enroll 1,782 participants.